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Résumé en
anglais
Creatine and guanidinoacetate are biomarkers of creatine metabolism. Their assays in
body fluids may be used for detecting patients with primary creatine deficiency
disorders (PCDD), a class of inherited diseases. Their laboratory values in blood and
urine may vary with age, requiring that reference normal values are given within the
age range. Despite the long known role of creatine for muscle physiology, muscle
signs are not necessarily the major complaint expressed by PCDD patients. These
disorders drastically affect brain function inducing, in patients, intellectual disability,
autistic behavior and other neurological signs (delays in speech and language,
epilepsy, ataxia, dystonia and choreoathetosis), being a common feature the drop in
brain creatine content. For this reason, screening of PCDD patients has been
repeatedly carried out in populations with neurological signs. This report is aimed at
providing reference laboratory values and related age ranges found for a large scale
population of patients with neurological signs (more than 6 thousand patients)
previously serving as a background population for screening French patients with
PCDD. These reference laboratory values and age ranges compare rather favorably
with literature values for healthy populations. Some differences are also observed, and
female participants are discriminated from male participants as regards to urine but
not blood values including creatine on creatinine ratio and guanidinoacetate on
creatinine ratio values. Such gender differences were previously observed in healthy
populations; they might be explained by literature differential effects of testosterone
and estrogen in adolescents and adults, and by estrogen effects in prepubertal age on
SLC6A8 function. Finally, though they were acquired on a population with
neurological signs, the present data might reasonably serve as reference laboratory
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